TherapeuticsMD, Inc. (TXMD): Price and Financial Metrics

TherapeuticsMD, Inc. (TXMD): $3.86

0.27 (+7.52%)

POWR Rating

Component Grades














  • TXMD scores best on the Value dimension, with a Value rank ahead of 87.1% of US stocks.
  • The strongest trend for TXMD is in Growth, which has been heading down over the past 179 days.
  • TXMD's current lowest rank is in the Quality metric (where it is better than 6.93% of US stocks).

TXMD Stock Summary

  • THERAPEUTICSMD INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.23% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.89 for THERAPEUTICSMD INC; that's greater than it is for only 4.67% of US stocks.
  • THERAPEUTICSMD INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 378.74%, greater than the shareholder yield of 99.1% of stocks in our set.
  • Stocks that are quantitatively similar to TXMD, based on their financial statements, market capitalization, and price volatility, are ACTG, NAOV, MTG, XTNT, and AMS.
  • TXMD's SEC filings can be seen here. And to visit THERAPEUTICSMD INC's official web site, go to

TXMD Valuation Summary

  • TXMD's price/sales ratio is 0.4; this is 78.95% lower than that of the median Healthcare stock.
  • TXMD's price/earnings ratio has moved up 12.5 over the prior 134 months.

Below are key valuation metrics over time for TXMD.

Stock Date P/S P/B P/E EV/EBIT
TXMD 2023-03-17 0.4 -0.7 -3.8 3.2
TXMD 2023-03-16 0.4 -0.7 -3.8 3.2
TXMD 2023-03-15 0.4 -0.7 -4.0 3.2
TXMD 2023-03-14 0.4 -0.7 -4.2 3.3
TXMD 2023-03-13 0.4 -0.8 -4.2 3.3
TXMD 2023-03-10 0.4 -0.8 -4.2 3.3

TXMD Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -137.17%.
  • Its 2 year price growth rate is now at -95.09%.
  • Its 3 year price growth rate is now at -98.3%.
Over the past 15 months, TXMD's revenue has gone up $2,701,410.

The table below shows TXMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 87.489 -103.408 -8.665
2022-06-30 91.978 -122.711 -27.12
2022-03-31 86.418 -133.839 -182.053
2021-12-31 86.951 -142.693 -172.415
2021-09-30 90.85079 -133.4563 -171.5426
2021-06-30 84.78759 -129.282 -156.7337

TXMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TXMD has a Quality Grade of D, ranking ahead of 19.35% of graded US stocks.
  • TXMD's asset turnover comes in at 0.419 -- ranking 109th of 682 Pharmaceutical Products stocks.
  • ALNY, QGEN, and CASI are the stocks whose asset turnover ratios are most correlated with TXMD.

The table below shows TXMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.419 0.791 -0.569
2021-03-31 0.361 0.752 -0.564
2020-12-31 0.311 0.754 -0.620
2020-09-30 0.254 0.772 -0.681
2020-06-30 0.253 0.817 -0.738
2020-03-31 0.225 0.857 -0.822

TXMD Price Target

For more insight on analysts targets of TXMD, see our TXMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.80 Average Broker Recommendation 1.38 (Strong Buy)

TXMD Stock Price Chart Interactive Chart >

Price chart for TXMD

TXMD Price/Volume Stats

Current price $3.86 52-week high $21.00
Prev. close $3.59 52-week low $1.99
Day low $3.44 Volume 59,700
Day high $3.90 Avg. volume 42,881
50-day MA $4.79 Dividend yield N/A
200-day MA $6.64 Market Cap 36.38M

TherapeuticsMD, Inc. (TXMD) Company Bio

TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company was founded in 2008 and is based in Boca Raton, Florida.

TXMD Latest News Stream

Event/Time News Detail
Loading, please wait...

TXMD Latest Social Stream

Loading social stream, please wait...

View Full TXMD Social Stream

Latest TXMD News From Around the Web

Below are the latest news stories about THERAPEUTICSMD INC that investors may wish to consider to help them evaluate TXMD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday!

William White on InvestorPlace | January 23, 2023

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

BOCA RATON, Fla., January 03, 2023--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products

Yahoo | January 3, 2023

Boca pharma company will cut 212 employees after failed buyout

Women's health care venture TherapeuticsMD will terminate its entire team of 212 employees by the end of the year, according to a Worker Adjustment and Retraining Notification notice submitted Dec. 6. The layoffs come after the cancellation of the pharmaceutical company's planned merger with Athene Merger, an affiliate of private equity firm EW Healthcare Partners.

Yahoo | December 8, 2022

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

BOCA RATON, Fla., December 04, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agree

Yahoo | December 4, 2022

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 15, 2022

Read More 'TXMD' Stories Here

TXMD Price Returns

1-mo -22.65%
3-mo -26.34%
6-mo -45.01%
1-year -80.72%
3-year -92.85%
5-year -98.47%
YTD -30.95%
2022 -68.55%
2021 -70.62%
2020 -50.00%
2019 -36.48%
2018 -36.92%

Continue Researching TXMD

Here are a few links from around the web to help you further your research on TherapeuticsMD Inc's stock as an investment opportunity:

TherapeuticsMD Inc (TXMD) Stock Price | Nasdaq
TherapeuticsMD Inc (TXMD) Stock Quote, History and News - Yahoo Finance
TherapeuticsMD Inc (TXMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8195 seconds.